Kleinwort Benson Investors Dublin Ltd purchased a new stake in Pfizer Inc. (NYSE:PFE) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,028,854 shares of the biopharmaceutical company’s stock, valued at approximately $71,436,000. Pfizer comprises about 1.9% of Kleinwort Benson Investors Dublin Ltd’s investment portfolio, making the stock its 10th largest position.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Stelac Advisory Services LLC acquired a new stake in Pfizer during the second quarter valued at about $110,000. Catamount Wealth Management raised its stake in Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 545 shares during the period. Commonwealth Financial Services LLC raised its stake in Pfizer by 5.5% in the second quarter. Commonwealth Financial Services LLC now owns 4,023 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 210 shares during the period. Stuart Chaussee & Associates Inc. raised its stake in Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 2,125 shares during the period. Finally, Jag Capital Management LLC acquired a new stake in Pfizer during the second quarter valued at about $202,000. Institutional investors and hedge funds own 69.65% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) traded up 1.65% on Friday, reaching $33.87. 27,809,992 shares of the company’s stock traded hands. The firm has a market cap of $205.44 billion, a P/E ratio of 30.03 and a beta of 0.87. The stock has a 50-day moving average of $34.51 and a 200 day moving average of $34.02. Pfizer Inc. has a 12-month low of $28.25 and a 12-month high of $37.39.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.02. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The company earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. During the same period in the prior year, the firm earned $0.56 earnings per share. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. On average, equities research analysts expect that Pfizer Inc. will post $2.46 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be issued a $0.30 dividend. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a yield of 3.54%. Pfizer’s dividend payout ratio is presently 95.24%.
PFE has been the topic of several research reports. Jefferies Group set a $41.50 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Thursday, July 14th. Vetr raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.08 price target on the stock in a research report on Tuesday, August 2nd. JPMorgan Chase & Co. set a $40.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, August 3rd. Credit Suisse Group AG reissued an “outperform” rating and issued a $40.00 price target on shares of Pfizer in a research report on Monday, August 22nd. Finally, BMO Capital Markets reaffirmed a “buy” rating and set a $40.00 target price on shares of Pfizer in a report on Thursday, July 21st. Ten equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $38.78.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.